JAQUELINE RIBEIRO SCHOLZ

Prof. Dr. JAQUELINE RIBEIRO SCHOLZ

orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 November 2022 in Arquivos Brasileiros de Cardiologia
Verified
Journal Article
Open access
PDF file
GOGlaucia Oliveira
Glaucia Oliveira
MAMaria Cristina Costa de Almeida
Maria Cristina Costa de Almeida
CMCeli Marques-Santos
Celi Marques-Santos
MCMaria Elizabeth Navegantes Caetano Costa
Maria Elizabeth Navegantes Caetano Costa
RCRegina Coeli Marques de Carvalho
Regina Coeli Marques de Carvalho
VLViviana de Mello Guzzo Lemke
Viviana de Mello Guzzo Lemke
Sumário Introdução 822 1. Destaques deste Posicionamento 823 […] Posicionamento sobre a Saúde Cardiovascular nas Mulheres – 2022 Sumário Introdução 822 1. Destaques deste Posicionamento 823 […] Posicionamento sobre a Saúde Cardiovascular nas Mulheres – 2022

16 May 2024 in Tobacco Induced Diseases
Verified
Journal Article
Open access
PGPatricia V. Gaya
Patricia V. Gaya
GFGuilherme Wesley Peixoto da Fonseca
Guilherme Wesley Peixoto da Fonseca
LTLucas Tsuyoshi Tanji
Lucas Tsuyoshi Tanji
TATania O. Abe
Tania O. Abe
MAMaria J N Alves
Maria J N Alves
JAQUELINE RIBEIRO SCHOLZJAQUELINE RIBEIRO SCHOLZ
JAQUELINE RIBEIRO SCHOLZ
Introduction: High blood pressure in hypertensive smokers is affected by nicotine consumption. This study aimed to evaluate the effect of smoking cessation treatments on blood pressure in hypertensive smokers. Methods: A total of 113 hypertensive smokers on antihypertensives during smoking...

13 October 2020 in Arquivos Brasileiros de Cardiologia
Verified
Journal Article
Open access
PDF file
JAQUELINE RIBEIRO SCHOLZJAQUELINE RIBEIRO SCHOLZ
JAQUELINE RIBEIRO SCHOLZ
MLMarcelo Antônio Cartaxo Queiroga Lopes
Marcelo Antônio Cartaxo Queiroga Lopes
JSJose Saraiva
Jose Saraiva
FCFernanda Consolim Colombo
Fernanda Consolim Colombo
The World Health Organization (WHO) declared COVID-19, an infection caused by the new Coronavirus (SARS-CoV-2), as a pandemic on March 11, 2020. By the beginning of June, 7 million positive cases and around 400 thousand deaths from the disease had been reported worldwide. In the same period, Brazil accounted for approximately 700 thousand cases and 40 thousand deaths. Although the virus can infect individuals of any age, so far the most serious cases have been described in people aged 55 [...] The World Health Organization (WHO) declared COVID-19, an infection caused by the new Coronavirus (SARS-CoV-2), as a pandemic on March 11, 2020. By the beginning of June, 7 million positive cases and around 400 thousand deaths from the disease had been reported worldwide. In the same period, Brazil accounted for approximately 700 thousand cases and 40 thousand deaths. Although the virus can infect individuals of any age, so far the most serious cases have been described in people aged 55

8 February 2024 in Arquivos Brasileiros de Cardiologia
Verified
Journal Article
Open access
PDF file
JAQUELINE RIBEIRO SCHOLZJAQUELINE RIBEIRO SCHOLZ
JAQUELINE RIBEIRO SCHOLZ
DMDeborah Malta
Deborah Malta
AFAntonio Aurélio de Paiva Fagundes
Antonio Aurélio de Paiva Fagundes
RPRicardo Pavanello
Ricardo Pavanello
GBGerson Luiz Bredt
Gerson Luiz Bredt
MRMário de Seixas Rocha
Mário de Seixas Rocha
10 Razões para Manter a Proibição […] Posicionamento da Sociedade Brasileira de Cardiologia sobre o Uso de Dispositivos Eletrônicos para Fumar – 2024 10 Razões para Manter a Proibição […] Posicionamento da Sociedade Brasileira de Cardiologia sobre o Uso de Dispositivos Eletrônicos para Fumar – 2024

1 December 2012 in Jornal Brasileiro de Pneumologia
Verified
Journal Article
Open access
PDF file
JAQUELINE RIBEIRO SCHOLZJAQUELINE RIBEIRO SCHOLZ
JAQUELINE RIBEIRO SCHOLZ
Smoking is considered the leading preventable cause of morbidity and mortality. The pharmacological management of nicotine withdrawal syndrome enables better cessation rates. In our smoking cessation program, we have developed a data collection system, which includes two new instruments: a score that assesses nicotine dependence in smokers of < 10 cigarettes/day; and a patient comfort scale to be used during smoking cessation treatment. Here, we describe the two instruments, both of which are still undergoing validation.

5 April 2018 in BMC Medical Genetics
Verified
Journal Article
Open access
PDF file
PTPaulo Roberto Xavier Tomaz
Paulo Roberto Xavier Tomaz
JSJuliana Rocha Santos
Juliana Rocha Santos
JAQUELINE RIBEIRO SCHOLZJAQUELINE RIBEIRO SCHOLZ
JAQUELINE RIBEIRO SCHOLZ
TATânia Ogawa Abe
Tânia Ogawa Abe
PGPatrícia Viviane Gaya
Patrícia Viviane Gaya
PSPaulo Santos
Paulo Santos
The identification of variants in the nicotinic acetylcholine receptor (nAChR) subunit genes associated with smoking phenotypes are increasingly important for prevention and treatment of nicotine dependence. In the context of personalized medicine, the aims of this study were to evaluate whether cholinergic receptor nicotinic alpha 2 (CHRNA2), cholinergic receptor nicotinic alpha 3 (CHRNA3), cholinergic receptor nicotinic alpha 5 (CHRNA5) and cholinergic receptor nicotinic beta 3 (CHRNB3) polymorphisms were associated with nicotine dependence severity, and to investigate possible pharmacogenetics markers of smoking cessation treatment. This study cohort enrolled 1049 smoking patients who received pharmacological treatment (varenicline, varenicline plus bupropion, bupropion plus/or nicotine replacement therapy). Smoking cessation success was considered for patients who completed 6 months of continuous abstinence. Fagerström test for nicotine dependence (FTND) and Issa situational smoking scores (Issa score) were analyzed for nicotine dependence. CHRNA2 (rs2472553), CHRNA3 (rs1051730), CHRNA5 (rs16969968 and rs2036527) and CHRNB3 (rs6474413) polymorphisms were genotyped by high resolution melting analysis. Females with GA and AA genotypes for CHRNA5 rs16969968 and rs2036527 polymorphisms had higher success rate in smoking cessation treatment: 44.0% and 56.3% (rs16969968), 41.5% and 56.5% (rs2036527), respectively, compared with carriers of the GG genotypes: 35.7% (rs16969968), 34.8% (rs2036527), (P = 0.03, n = 389; P = 0.01, n = 391). The GA or AA genotypes for the rs16969968 and rs2036527 were associated with higher odds ratio for success in women (OR = 1.63; 95% CI = 1.04 to 2.54; P = 0.03 and OR = 1.59, 95% CI = 1.02 to 2.48; P = 0.04; respectively). We did not find association of these polymorphisms with nicotine dependence related scores. Polymorphisms in the CHRNA2, CHRNA3 and CHRNB3 genes were not associated with the phenotypes studied. CHRNA5 rs16969968 and rs2036527 were associated with higher success rate in the smoking cessation treatment in women. These findings might contribute to advances in personalized medicine.